Signals
5Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Keratoconus therapy widens past corneal cross-linking
Corneal cross-linking adoption, intracorneal ring segment maturity, and emerging custom cross-linking and topography-guided treatment are reshaping keratoconus management.
Glaucoma drug-delivery implant uptake reveals the procedure-room workflow constraint
Sustained-release glaucoma drug-delivery implants are addressing the chronic adherence problem that has characterised glaucoma management for decades. Real-world uptake reveals the procedure-room workflow as the principal access constraint.
Geographic atrophy therapy uptake reveals the disease-monitoring infrastructure gap
Real-world uptake of complement C3 and C5 inhibitors for geographic atrophy has been slower and more variable than the pivotal trial benefit profile would have predicted. The drivers are disease-monitoring infrastructure, intravitreal-injection capacity, and the patient-and-clinician decision frame around a slowly progressive condition.
Snapshots
2Presbyopia therapy reference (2026)
Reference snapshot of presbyopia management across optical, surgical, and pharmacological approaches.
Thyroid eye disease therapy reference (2026)
Reference snapshot of thyroid eye disease therapy across active and stable phases.
Explained
2What is presbyopia?
Plain-language primer on presbyopia, why it affects nearly everyone with age, and what the modern range of options can offer.
How ophthalmic drug delivery has moved from formulation chemistry to device engineering
Ophthalmic drug delivery has shifted in the past decade from a primarily formulation-chemistry exercise (eye drops, conventional intravitreal injection) into a device-engineering one (sustained-release implants, port-delivery systems, microneedle and suprachoroidal delivery). The methodology and the implications for commercial planning are worth understanding.